Click on a filter below to refine your search. Remove a filter to broaden your search.
A reduced risk of hospitalization or death was seen at 28 days; a lower risk was seen for all individual mAb products.
Noninferiority was established with respect to time to sustained clinical recovery for adults at high risk for progression.
Years of life lost increased 35.7% per COVID-19 death in 2021 versus 2020 as median age of COVID-19 deaths decreased.
Virologic rebound was more common among those who started therapy within two days of symptom onset.
Those who survived COVID-19 had reduced mortality on days 181 to 365 and 366 to 730.
Associations were seen for overall sleep quality, deterioration in sleep quality after admission and sleep regularity with higher dyspnea scores.
The global seroprevalence from infection or vaccination reached 59.2% by September 2021.
Compared with those without COVID-19, similar deficits were seen for those in whom symptoms resolved in less than four or at least 12 weeks.
Reductions in COVID-19 cases and deaths among residents at skilled nursing facilities mainly were seen before vaccine availability.
The findings were seen regardless of vaccination status and history of prior infection.